Yijia Medical Technology has completed a Pre-A+ financing round totaling nearly 100 million yuan to advance its urology and pelvic health innovation initiatives.

Target Information

益佳达医疗科技（上海）有限公司, also known as Yijia, has successfully secured nearly 100 million yuan in a Pre-A+ round of financing. This funding round was jointly led by Shanlan Capital and Yuanjing Capital, with Hetang Venture Capital participating as well. The proceeds from this financing will be used to continue innovation in Yijia's product line dedicated to urology and pelvic health, as well as to expand its pipeline and conduct clinical research. Previously, Huachuang Capital invested exclusively in Yijia during its angel round.

Industry Overview in the Target's Country

The urology sector represents a significant and lucrative market worldwide, with a valuation reaching $38 billion in 2021. This market is projected to grow at a rate of approximately 5% annually. The urology path has also become an active direction for capital investment; for instance, Boston Scientific's acquisition of the surgical laser business from Coloplast for $1.07 billion in 2021 highlights the attention that major corporations are investing in high-quality urological products.

In China, the patient base suffering from urological disorders is considerable. As living standards improve, along with a shift in public awareness and a significant rise in the localization of medical devices and materials, there has been a noticeable increase in the diagnosis r